PCML
ARQT icon

Pavaki Capital Management LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

Pavaki Capital Management LLC’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9M Hold
187,000
– – 1.71% 13
2026
Q1 		$4.41M Sell
187,000
-15,000
-7% -$383K 1.87% 13
2025
Q4 		$5.87M Buy
+202,000
New +$5.17M 2.3% 9

Other funds holding ARQT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Pavaki Capital Management LLC's ARQT Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 187,000 shares worth $4.9M. The position accounts for 1.71% of the portfolio, ranked #13.

Pavaki Capital Management LLC first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.87M in Q4 2025. 86 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Pavaki Capital Management LLC held 187,000 shares of Arcutis Biotherapeutics worth $4.9M as of Q2 2026.
  • Pavaki Capital Management LLC left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 1.71% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #13 holding.
  • Pavaki Capital Management LLC first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's Arcutis Biotherapeutics position peaked at $5.87M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.